As shown in Figure 4, an analysis of the overall survival of HCC patients stratified by serum visfatin levels suggests that HCC patients with high serum visfatin levels had significantly shorter overall survival times than those with low serum visfatin levels (P<0.001). The gene discussed is NAMPT; the disease is hepatocellular carcinoma.